ClinicalTrials.gg
Active, not recruitingNCT04775082Updated Nov 16, 2026Results posted

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

A Phase 3 interventional study of Liraglutide and Placebo in Obesity, sponsored by Novo Nordisk A/S. Active, not recruiting at 32 sites in 9 countries. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Updated Nov 16, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 79 studies testing liraglutide in Obesity — 7 open to participants now, 9 under way, 2 of them phase 3. Liraglutide · Obesity.

Enrollment
32nd of 79
82 · median 70
Started
2021
with 4 others
Phase 3
17 of 79
1 open now
Registered
66th of 79
by date
Lead sponsor
16 of 79
Novo Nordisk A/S

Among the 79 studies testing liraglutide in Obesity, this one is the 32nd largest by enrollment, is one of 5 that started in 2021, is one of 17 in phase 3, and was the 66th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

7 of the 79 studies testing liraglutide in Obesity are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies testing liraglutide in Obesity, or all of them as a file.
02

Study summary

The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects.

Participants will either get liraglutide or placebo. Which treatment the participants get is decided by chance. Liraglutide is a new medicine for children, but it can already be prescribed by doctors to adults with overweight or obesity. The participant will get 1 injection every day.

In addition to taking the medicine, the participants will have talks with the study staff about healthy food choices, how they can be more physically active and what can be done to help the participants to lose weight.

The study will last for about 96 weeks (almost 2 years). The participants will have 18 clinic visits and 10 phone or video calls with the study doctor/staff. Participant will have blood samples taken, have 1 test to check the heart, 1 hand X-ray taken and must fill in a diary between some of the visits.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • of parent(s) or legally acceptable representative of subject and child assent, as age-appropriate, obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
  • Male or female, aged 6 to below 12 years at the time of signing informed consent
  • Tanner stage 1-5 pubertal development at the time of signing informed consent
  • above or equal to 95th percentile, on gender and age-specific growth charts (CDC.gov)
  • History of failing to lose sufficient weight with lifestyle modification as judged by the investigator

For subjects with type 2 diabetes at screening the following inclusion criterion apply in addition:

- (HbA1c) below or equal to 10.0 percent (86 mmol/mol) as measured by central laboratory at screening

Exclusion criteria

Exclusion Criteria:

  • A self-reported (or by parent(s)/LAR (legally acceptable representative) where applicable) change in body weight above 5 kg (11 lbs) within 90 days before screening irrespective of medical records
  • Treatment with any medication for the indication of obesity within the past 90 days before screening
  • Type 1 diabetes
  • Subjects with secondary causes of obesity (for example hypothalamic, monogenic or endocrine causes)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Liraglutide 3.0 mg

    The treatment duration is 56 weeks and the follow-up period is 26 weeks.

    Drug: Liraglutide

  • Placebo comparator
    Placebo

    The treatment duration is 56 weeks and the follow-up period is 26 weeks.

    Drug: Placebo

Interventions

  • The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily. The dose will increase each week over 4 or 5 weeks until the final dose is reached.

  • DrugPlacebo

    The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.

06

What researchers measure

Primary outcomes

  1. Relative Change in Body Mass Index (BMI)

    Relative change in BMI from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.

    Time frame: Baseline (week 0), week 56

Secondary outcomes

  1. Relative Change in Body Weight (Percentage)

    Relative change in body weight (Percentage) from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.

    Time frame: Baseline (week 0), week 56

  2. Percentage of Participants Achieving More Than or Equal to (≥) 5% Reduction of BMI

    Percentage of participants who achieved more than or equal to (≥) 5% reduction in their baseline (week 0) BMI at week 56 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 5% reduction in their baseline (week 0) BMI at week 56 and 'No' infers percentage of participants who did not achieve ≥ 5% reduction in their baseline (week 0) BMI at week 56. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.

    Time frame: At week 56

  3. Change in Body Weight (Kilogram)

    Change in body weight (Kilogram) from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.

    Time frame: Baseline (week 0), week 56

  4. Change in BMI Standard Deviation Score (WHO.Int)

    Change in BMI SDS (BMI-for-age-and-sex Z-score) was calculated as the Week 56 score minus the baseline (Week 0) score. BMI Z-scores were calculated using World Health Organization (WHO) age- and sex-specific reference values and the formula Z=\[(BMI/M)\^L-1\]/(L×S), where M is the median BMI, L is the Box-Cox power accounting for skewness, and S is the coefficient of variation. A BMI Z-score of 0 represents the age- and sex-specific population mean. According to the WHO growth reference, BMI-for-age values greater than (\>) +1 SD and \>+2 SD correspond approximately to overweight and obesity, respectively. Positive Z-scores indicate BMI SDS values above the age- and sex-specific population mean, whereas negative Z-scores indicate values below the age- and sex-specific population mean. For change from baseline, negative values indicate a decrease in BMI SDS (favourable outcome), positive values indicate an increase in BMI SDS (unfavourable outcome), and 0 indicates no change.

    Time frame: Baseline (week 0), week 56

  5. Percentage of Participants Achieving ≥10% Reduction of BMI

    Percentage of participants achieving more than or equal to (≥) 10% reduction in their baseline (week 0) BMI at week 56 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 10% reduction in their baseline (week 0) BMI at week 56 and 'No' infers percentage of participants who did not achieve ≥ 10% reduction in their baseline (week 0) BMI at week 56. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.

    Time frame: At week 56

  6. Change in BMI Percentage of the 95th Percentile on Gender and Age-specific Growth Charts (CDC.Gov [CDC: {Centers for Disease Control and Prevention}])

    Change in BMI percentage of the 95th percentile on gender and age-specific growth charts (CDC.gov) from baseline (week 0) to week 56 is presented. CDC gender and age-specific growth charts: normal (BMI less than \[\<\] 85th percentile), overweight (BMI greater than or equal to \[\>=\] 85th - \<95th percentile), obesity class I (BMI \>=95th - \<120% of the 95th percentile), obesity class II (BMI \>=120% of the 95th percentile - \<140% of the 95th percentile) and obesity class III (BMI \>=140% of the 95th percentile). The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.

    Time frame: Baseline (week 0), week 56

  7. Change in Waist Circumference

    Change in waist circumference from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.

    Time frame: Baseline (week 0), week 56

  8. Change in Systolic Blood Pressure

    Change in systolic blood pressure from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.

    Time frame: Baseline (week 0), week 56

  9. Change in Diastolic Blood Pressure

    Change in diastolic blood pressure from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.

    Time frame: Baseline (week 0), week 56

  10. Change in Glycated Haemoglobin (HbA1c)

    Change in glycated haemoglobin (HbA1c) from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.

    Time frame: Baseline (week 0), week 56

  11. Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical trial participant administered or using a medicinal product, whether or not considered related to the medicinal product or usage. The endpoint was evaluated based on the data from On-treatment period which was defined as events with onset date between the first day of study product administration and whatever comes first: a) 14 days after the last day on study product, b) first follow up visit (V24 for participants with study product discontinued), or c) last study visit (participants withdrawn without follow-up visit).

    Time frame: From baseline (week 0) to week 82

  12. Treatment Emergent Serious Adverse Events (SAEs)

    An SAE is an AE that fulfils at least one of the following criteria: 1) results in death; 2) is life-threatening; 3) requires inpatient hospitalisation or prolongation of existing hospitalisation; 4) results in persistent disability/incapacity; 5) is a congenital anomaly/birth defect; 6) important medical event. The endpoint was evaluated based on the data from On-treatment period which was defined as events with onset date between the first day of study product administration and whatever comes first: a) 14 days after the last day on study product, b) first follow up visit (V24 for participants with study product discontinued), or c) last study visit (participants withdrawn without follow-up visit).

    Time frame: From baseline (week 0) to week 82

07

Results

Posted Nov 16, 2026

Participant flow

This trial was conducted at 25 sites that enrolled participants in Belgium, India, Israel, Malaysia, Mexico, Portugal, Russia, Switzerland and the United States.

Participant flow — Overall Study
MilestoneLiraglutide 3.0 mgPlacebo
Started5626
Completed4422
Not completed124
Withdrew: Other21
Withdrew: Withdrawal by subject11
Withdrew: Technical problems10
Withdrew: Lost to follow-up11
Withdrew: Lack of efficacy11
Withdrew: Adverse event60

Outcome measures

PrimaryRelative Change in Body Mass Index (BMI)

Relative change in BMI from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.

Time frame:
Baseline (week 0), week 56
Reported as:
Mean · Percentage (%) change of BMI
Relative Change in Body Mass Index (BMI)
Percentage (%) change of BMILiraglutide 3.0 mgPlacebo
Relative Change in Body Mass Index (BMI)-6.7 ± 9.62.1 ± 6.1
Statistical analysis
  • Liraglutide 3.0 mg vs Placebo · ANCOVA · p = 0.0005 · Treatment difference: -7.40 · 95% CI -11.56 to -3.24
  • Liraglutide 3.0 mg vs Placebo · Mixed Models Analysis · p = 0.0003 · Treatment difference: -8.26 · 95% CI -12.55 to -3.96
SecondaryRelative Change in Body Weight (Percentage)

Relative change in body weight (Percentage) from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.

Time frame:
Baseline (week 0), week 56
Reported as:
Mean · Percentage (%) change of body weight
Relative Change in Body Weight (Percentage)
Percentage (%) change of body weightLiraglutide 3.0 mgPlacebo
Relative Change in Body Weight (Percentage)0.4 ± 10.710.2 ± 6.8
SecondaryPercentage of Participants Achieving More Than or Equal to (≥) 5% Reduction of BMI

Percentage of participants who achieved more than or equal to (≥) 5% reduction in their baseline (week 0) BMI at week 56 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 5% reduction in their baseline (week 0) BMI at week 56 and 'No' infers percentage of participants who did not achieve ≥ 5% reduction in their baseline (week 0) BMI at week 56. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.

Time frame:
At week 56
Reported as:
Number · Percentage (%) of participants
Percentage of Participants Achieving More Than or Equal to (≥) 5% Reduction of BMI
Percentage (%) of participantsLiraglutide 3.0 mgPlacebo
Yes46.28.7
No53.891.3
SecondaryChange in Body Weight (Kilogram)

Change in body weight (Kilogram) from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.

Time frame:
Baseline (week 0), week 56
Reported as:
Mean · Kilogram (kg)
Change in Body Weight (Kilogram)
Kilogram (kg)Liraglutide 3.0 mgPlacebo
Change in Body Weight (Kilogram)0.1 ± 8.27.5 ± 5.3
SecondaryChange in BMI Standard Deviation Score (WHO.Int)

Change in BMI SDS (BMI-for-age-and-sex Z-score) was calculated as the Week 56 score minus the baseline (Week 0) score. BMI Z-scores were calculated using World Health Organization (WHO) age- and sex-specific reference values and the formula Z=\[(BMI/M)\^L-1\]/(L×S), where M is the median BMI, L is the Box-Cox power accounting for skewness, and S is the coefficient of variation. A BMI Z-score of 0 represents the age- and sex-specific population mean. According to the WHO growth reference, BMI-for-age values greater than (\>) +1 SD and \>+2 SD correspond approximately to overweight and obesity, respectively. Positive Z-scores indicate BMI SDS values above the age- and sex-specific population mean, whereas negative Z-scores indicate values below the age- and sex-specific population mean. For change from baseline, negative values indicate a decrease in BMI SDS (favourable outcome), positive values indicate an increase in BMI SDS (unfavourable outcome), and 0 indicates no change.

Time frame:
Baseline (week 0), week 56
Reported as:
Mean · Z-score
Change in BMI Standard Deviation Score (WHO.Int)
Z-scoreLiraglutide 3.0 mgPlacebo
Change in BMI Standard Deviation Score (WHO.Int)-0.78 ± 0.58-0.34 ± 0.33
SecondaryPercentage of Participants Achieving ≥10% Reduction of BMI

Percentage of participants achieving more than or equal to (≥) 10% reduction in their baseline (week 0) BMI at week 56 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 10% reduction in their baseline (week 0) BMI at week 56 and 'No' infers percentage of participants who did not achieve ≥ 10% reduction in their baseline (week 0) BMI at week 56. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.

Time frame:
At week 56
Reported as:
Number · Percentage (%) of participants
Percentage of Participants Achieving ≥10% Reduction of BMI
Percentage (%) of participantsLiraglutide 3.0 mgPlacebo
Yes34.64.3
No65.495.7
SecondaryChange in BMI Percentage of the 95th Percentile on Gender and Age-specific Growth Charts (CDC.Gov [CDC: {Centers for Disease Control and Prevention}])

Change in BMI percentage of the 95th percentile on gender and age-specific growth charts (CDC.gov) from baseline (week 0) to week 56 is presented. CDC gender and age-specific growth charts: normal (BMI less than \[\<\] 85th percentile), overweight (BMI greater than or equal to \[\>=\] 85th - \<95th percentile), obesity class I (BMI \>=95th - \<120% of the 95th percentile), obesity class II (BMI \>=120% of the 95th percentile - \<140% of the 95th percentile) and obesity class III (BMI \>=140% of the 95th percentile). The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.

Time frame:
Baseline (week 0), week 56
Reported as:
Mean · % change in BMI% of the 95th percentile
Change in BMI Percentage of the 95th Percentile on Gender and Age-specific Growth Charts (CDC.Gov [CDC: {Centers for Disease Control and Prevention}])
% change in BMI% of the 95th percentileLiraglutide 3.0 mgPlacebo
Change in BMI Percentage of the 95th Percentile on Gender and Age-specific Growth Charts (CDC.Gov [CDC: {Centers for Disease Control and Prevention}])-15.1 ± 12.9-3.4 ± 7.4
SecondaryChange in Waist Circumference

Change in waist circumference from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.

Time frame:
Baseline (week 0), week 56
Reported as:
Mean · Centimeter (cm)
Change in Waist Circumference
Centimeter (cm)Liraglutide 3.0 mgPlacebo
Change in Waist Circumference-1.89 ± 8.343.06 ± 7.74
SecondaryChange in Systolic Blood Pressure

Change in systolic blood pressure from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.

Time frame:
Baseline (week 0), week 56
Reported as:
Mean · Millimeters of mercury (mmHg)
Change in Systolic Blood Pressure
Millimeters of mercury (mmHg)Liraglutide 3.0 mgPlacebo
Change in Systolic Blood Pressure-2 ± 100 ± 13
SecondaryChange in Diastolic Blood Pressure

Change in diastolic blood pressure from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.

Time frame:
Baseline (week 0), week 56
Reported as:
Mean · mmHg
Change in Diastolic Blood Pressure
mmHgLiraglutide 3.0 mgPlacebo
Change in Diastolic Blood Pressure-1 ± 100 ± 10
SecondaryChange in Glycated Haemoglobin (HbA1c)

Change in glycated haemoglobin (HbA1c) from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.

Time frame:
Baseline (week 0), week 56
Reported as:
Mean · Percentage change in HbA1c
Change in Glycated Haemoglobin (HbA1c)
Percentage change in HbA1cLiraglutide 3.0 mgPlacebo
Change in Glycated Haemoglobin (HbA1c)-0.2 ± 0.20.0 ± 0.2
SecondaryTreatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical trial participant administered or using a medicinal product, whether or not considered related to the medicinal product or usage. The endpoint was evaluated based on the data from On-treatment period which was defined as events with onset date between the first day of study product administration and whatever comes first: a) 14 days after the last day on study product, b) first follow up visit (V24 for participants with study product discontinued), or c) last study visit (participants withdrawn without follow-up visit).

Time frame:
From baseline (week 0) to week 82
Reported as:
Number · Number of events
Treatment Emergent Adverse Events (TEAEs)
Number of eventsLiraglutide 3.0 mgPlacebo
Treatment Emergent Adverse Events (TEAEs)436156
SecondaryTreatment Emergent Serious Adverse Events (SAEs)

An SAE is an AE that fulfils at least one of the following criteria: 1) results in death; 2) is life-threatening; 3) requires inpatient hospitalisation or prolongation of existing hospitalisation; 4) results in persistent disability/incapacity; 5) is a congenital anomaly/birth defect; 6) important medical event. The endpoint was evaluated based on the data from On-treatment period which was defined as events with onset date between the first day of study product administration and whatever comes first: a) 14 days after the last day on study product, b) first follow up visit (V24 for participants with study product discontinued), or c) last study visit (participants withdrawn without follow-up visit).

Time frame:
From baseline (week 0) to week 82
Reported as:
Number · Number of events
Treatment Emergent Serious Adverse Events (SAEs)
Number of eventsLiraglutide 3.0 mgPlacebo
Treatment Emergent Serious Adverse Events (SAEs)122

Adverse events

Collected over From baseline (week 0) to week 82. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Liraglutide 3.0 mg0/56 (0%)7/56 (12.5%)47/56 (83.9%)
Placebo0/26 (0%)2/26 (7.7%)22/26 (84.6%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventLiraglutide 3.0 mgPlacebo
VomitingGastrointestinal disorders3/560/26
Limb injuryInjury, poisoning and procedural complications0/561/26
Suicide attemptPsychiatric disorders0/561/26
AsthmaRespiratory, thoracic and mediastinal disorders1/560/26
ColitisGastrointestinal disorders1/560/26
Dengue feverInfections and infestations1/560/26
EpilepsyNervous system disorders1/560/26
HeadacheNervous system disorders1/560/26
MigraineNervous system disorders1/560/26
NauseaGastrointestinal disorders1/560/26
Most frequent other events
Showing 10 of 33
Most frequent other events
EventLiraglutide 3.0 mgPlacebo
VomitingGastrointestinal disorders35/564/26
NauseaGastrointestinal disorders25/565/26
DiarrhoeaGastrointestinal disorders19/567/26
COVID-19Infections and infestations11/566/26
HeadacheNervous system disorders8/566/26
ContusionInjury, poisoning and procedural complications4/565/26
PyrexiaGeneral disorders5/565/26
Abdominal pain upperGastrointestinal disorders10/564/26
NasopharyngitisInfections and infestations9/562/26
Abdominal painGastrointestinal disorders7/564/26

Baseline characteristics

The full analysis set (FAS) included all randomised participants according to the intention-to-treat principle, i.e., participants were included according to planned treatment.

Age, Continuous
Age, Continuous(Years)Liraglutide 3.0 mgPlaceboTotal
Mean10 ± 210 ± 210 ± 2
Sex: Female, Male
Sex: Female, Male(Participants)Liraglutide 3.0 mgPlaceboTotal
Female261238
Male301444
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Liraglutide 3.0 mgPlaceboTotal
Hispanic or Latino10111
Not Hispanic or Latino462571
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Liraglutide 3.0 mgPlaceboTotal
American Indian or Alaska Native101
Asian628
Native Hawaiian or Other Pacific Islander000
Black or African American426
White372259
More than one race000
Unknown or Not Reported808
08

Study locations

32 sites
09

References and documents

Publications

  • Fox CK, Barrientos-Perez M, Bomberg EM, Dcruz J, Gies I, Harder-Lauridsen NM, Jalaludin MY, Sahu K, Weimers P, Zueger T, Arslanian S; SCALE Kids Trial Group. Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial. N Engl J Med. 2025 Feb 6;392(6):555-565. doi: 10.1056/NEJMoa2407379. Epub 2024 Sep 10. PubMed 39258838 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Aug 2023, 28 months.

Results were first posted in Nov 2026, 3 years 3 months after primary completion. A results delay was requested in Jul 2024.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 28 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2021
First posted
Mar 1, 2021
StartActual
Mar 4, 2021
Primary completionActual
Aug 1, 2023
CompletionEst.
Feb 8, 2027
Results delay requested
Jul 25, 2024
Results first posted
Nov 16, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 16, 2026
Enrollment
78 (estimated)→82 (actual)
Nov 16, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedRelative changeChange in BMIBody Mass Index (Body mass indexBMI)Time frame: From baseline (week 0) to week 56 → Baseline (week 0), week 56
Nov 16, 2026
Documents
Secondary outcomes
10 edited, 2 added, 1 removed
What changed in the outcomes
  • EditedRelative changeChange in body weightBody Weight (Percentage)Time frame: From baseline (week 0) to week 56 → Baseline (week 0), week 56
  • EditedChange in BMI standard deviation scoreStandard Deviation Score (WHO.intInt)Time frame: From baseline (week 0) to week 56 → Baseline (week 0), week 56
  • EditedSubjects achieving abovePercentage of Participants Achieving More Than or equalEqual to (≥) 5 percent reduction% Reduction of BMITime frame: From baseline (week 0) to week 56 → At week 56
  • EditedChange in BMI percentagePercentage of the 95th percentilePercentile on genderGender and ageAge-specific growth chartsGrowth Charts (CDC.govGov [CDC: {Centers for Disease Control and Prevention}])Time frame: From baseline (week 0) to week 56 → Baseline (week 0), week 56
  • EditedChange in waist circumferenceWaist CircumferenceTime frame: From baseline (week 0) to week 56 → Baseline (week 0), week 56
  • EditedChange in systolic blood pressureSystolic Blood PressureTime frame: From baseline (week 0) to week 56 → Baseline (week 0), week 56
  • EditedChange in diastolic blood pressureDiastolic Blood PressureTime frame: From baseline (week 0) to week 56 → Baseline (week 0), week 56
  • EditedChange in HbA1cBody Weight (glycated haemoglobinKilogram)Time frame: From baseline (week 0) to week 56 → Baseline (week 0), week 56
  • EditedTreatment emergent adverse eventsEmergent Adverse Events (TEAEs)Time frame: From baseline (week 0) to week 82
  • EditedTreatment emergent serious adverse eventsEmergent Serious Adverse Events (SAEs)Time frame: From baseline (week 0) to week 82
  • AddedPercentage of Participants Achieving ≥10% Reduction of BMITime frame: At week 56
  • AddedChange in Glycated Haemoglobin (HbA1c)Time frame: Baseline (week 0), week 56
  • RemovedSubjects achieving above or equal to 10 percent reduction of BMITime frame: From baseline (week 0) to week 56
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Results posted
    Enrollment 78 (estimated)→82 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedRelative changeChange in BMIBody Mass Index (Body mass indexBMI)Time frame: From baseline (week 0) to week 56 → Baseline (week 0), week 56
    Secondary outcomes 10 edited, 2 added, 1 removed
    What changed in the outcomes
    • EditedRelative changeChange in body weightBody Weight (Percentage)Time frame: From baseline (week 0) to week 56 → Baseline (week 0), week 56
    • EditedChange in BMI standard deviation scoreStandard Deviation Score (WHO.intInt)Time frame: From baseline (week 0) to week 56 → Baseline (week 0), week 56
    • EditedSubjects achieving abovePercentage of Participants Achieving More Than or equalEqual to (≥) 5 percent reduction% Reduction of BMITime frame: From baseline (week 0) to week 56 → At week 56
    • EditedChange in BMI percentagePercentage of the 95th percentilePercentile on genderGender and ageAge-specific growth chartsGrowth Charts (CDC.govGov [CDC: {Centers for Disease Control and Prevention}])Time frame: From baseline (week 0) to week 56 → Baseline (week 0), week 56
    • EditedChange in waist circumferenceWaist CircumferenceTime frame: From baseline (week 0) to week 56 → Baseline (week 0), week 56
    • EditedChange in systolic blood pressureSystolic Blood PressureTime frame: From baseline (week 0) to week 56 → Baseline (week 0), week 56
    • EditedChange in diastolic blood pressureDiastolic Blood PressureTime frame: From baseline (week 0) to week 56 → Baseline (week 0), week 56
    • EditedChange in HbA1cBody Weight (glycated haemoglobinKilogram)Time frame: From baseline (week 0) to week 56 → Baseline (week 0), week 56
    • EditedTreatment emergent adverse eventsEmergent Adverse Events (TEAEs)Time frame: From baseline (week 0) to week 82
    • EditedTreatment emergent serious adverse eventsEmergent Serious Adverse Events (SAEs)Time frame: From baseline (week 0) to week 82
    • AddedPercentage of Participants Achieving ≥10% Reduction of BMITime frame: At week 56
    • AddedChange in Glycated Haemoglobin (HbA1c)Time frame: Baseline (week 0), week 56
    • RemovedSubjects achieving above or equal to 10 percent reduction of BMITime frame: From baseline (week 0) to week 56
    + 4 other changes: verification date, registry dates, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04775082
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 1, 2021
Start date
Mar 4, 2021
Primary completion
Aug 1, 2023
Completion
Feb 8, 2027 (estimated)
Results posted
Nov 16, 2026
Last update
Nov 16, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion